Somatostatin and Olfactory System {#S1}
=================================

Somatostatin-14 (SST-14), a peptide composed of 14 amino acids, was first detected in the hypothalamus and was shown to inhibit the secretion of growth hormone ([@B5]). Later, SST-28 was identified in the intestine ([@B36]). Both were derived from the same prohormone and showed similar affinity to at least six SST receptors (SSTR1--5, two isoforms SSTR2A--2B). These receptors are members of the G-protein-coupled seven-transmembrane domain receptor family, which are broadly expressed in the brain, including all olfactory structures ([@B34]).

Approximately 20% of neurons in the cerebral cortex are interneurons, most of them expressing γ-amino-butyric acid (GABA) and divided into three non-overlapping classes: parvalbumin-expressing, 5-HT3A receptor-expressing and somatostatin-expressing populations ([@B40]). This latter population can be, in turn, morphologically divided into Martinotti cells and non-Martinotti cells (among others, long-range projecting interneurons, basket cells and double-bouquet cells). Their axons typically target the distal dendrites of pyramidal cells (contrary to parvalbumin-expressing cells), creating a dense wiring into the local network with high basal firing activity that continues in the absence of synaptic input ([@B56]). The pivotal role of somatostatin-positive interneurons on disinhibition (inhibiting GABAergic interneurons and promoting pyramidal cell activation) has been recently demonstrated, and it appears to be essential for long-term regulation and network metaplasticity, which may be important for hippocampal-dependent learning and memory ([@B1]). During development, cortical interneurons including somatostatin-positive cells derive from the medial ganglionic eminence ([@B21]), while those interneurons reaching the olfactory bulb originate in the lateral ganglionic eminence ([@B59]). Importantly, olfactory system together with the hippocampus constitutes a neurogenic niche during adulthood and specific interneuron population are periodically replaced ([@B27]).

Olfactory sensory neurons are placed in the olfactory epithelium in the nasal cavity and send their axons to the olfactory bulb where primary olfactory information is processed. From here, the main cells (mitral and tufted cells) then send their projections to the rest of the olfactory cortices: anterior olfactory nucleus, olfactory tubercle, piriform cortex, amygdala, and entorhinal cortex ([@B30]). The anterior olfactory nucleus is a key structure that constitutes the first relay of olfactory information and it also sends ipsilateral and contralateral projections to the rest of olfactory areas ([@B7]). The piriform cortex is considered as the principal olfactory cortex and it is mainly involved in odor perception ([@B10]). Specifically, the amygdala and the entorhinal cortices are multimodal areas that receive olfactory information, among others, and in turn send projections to the hippocampus ([@B31]). This latter circuit participates in olfactory emotion and olfactory memory formation ([@B22]).

Somatostatin -expressing cells are present in all olfactory areas as well as SSTRs. In mouse, SST is expressed in the granule cell layer and within the inner part of the external plexiform layer in the olfactory bulb ([@B25]) and within the different subregions of the anterior olfactory nucleus ([@B8]). Regarding the olfactory cortices, SST-expressing cells are located mostly in layers II and III, while terminal axons target dendrites in layer I of the piriform cortex ([@B52]). In the amygdala, SST is present in deeper layers of olfactory cortical subregions, although non-olfactory central nucleus accumulates the highest levels ([@B38]). The olfactory entorhinal cortex, thus corresponding to the lateral entorhinal cortex, contains large number of SST interneurons and fibers in all layers ([@B60]). On the other hand, SSTRs1--4 are specifically distributed within the olfactory bulb ([@B33]) and they are highly expressed in the piriform cortex, olfactory amygdala, namely anterior cortical and posteromedial cortical nuclei and within the entorhinal cortex ([@B6]; [@B16]; [@B19]). Interestingly, SSTR5 is absent within the olfactory system with the exception of the olfactory tubercle ([@B17]). In human brain, SST interneurons are present in all olfactory areas ([Figure 1](#F1){ref-type="fig"}). In the olfactory bulb SST is sparse within the EPL while its expression is very abundant around the anterior olfactory nucleus ([Figures 1A,A',A",B,B](#F1){ref-type="fig"}'; [@B49]). SST is also present in the piriform cortex, particularly in layers II and III ([@B44]). Interestingly, the piriform cortex is divided into two different portions, namely the anterior portion placed at the frontal cortex and a posterior portion located at the temporal lobe ([Figures 1C,C'](#F1){ref-type="fig"}). Temporal lobe also includes key olfactory areas involved in olfactory memory formation such as the amygdala and the entorhinal cortex ([@B23]). SST is present in all amygdaloid nuclei including cortical olfactory amygdala ([@B55]) and in all layers of the entorhinal cortex ([Figures 1D,D',D"](#F1){ref-type="fig"}; [@B9]). SSTRs studies in human brain mostly show distribution patterns regarding neocortex and/or limbic system including the amygdala and the hippocampal formation, while olfactory system is still poorly examined ([@B39]; [@B46]).

![Scheme of the human olfactory system based on Nissl staining including the olfactory bulb **(A)** including different portions of the anterior olfactory nucleus (asterisks), the olfactory peduncle **(B)**, the piriform cortex **(C)**, the amygdala and the entorhinal cortex **(D)**. Bregma levels are indicated based on human brain atlas ([@B28]). Somatostatin cells (purple) localization and their variation regarding Alzheimer's and Parkinson's diseases are specified as described in the literature. High magnification images show **(A')** the different layers and **(A")** the anterior olfactory nucleus within olfactory bulb. Note the representation of the first olfactory relay placed in the glomeruli (orange circle) between the axons coming from the olfactory neurons forming the olfactory nerve (blue line) and the dendrites of mitral cells. Then, the mitral cells form the olfactory tract (green line), which projects over all olfactory areas. **(B')** represents the site of entry of the references from mitral cells into cortex in the frontal lobe, where the retrobulbar portion of the anterior olfactory nucleus can be observed. Once the olfactory peduncle contacts with cortex two different olfactory tracts appear **(C)**; the medial olfactory tract (contralateral projections) and the lateral olfactory tract (ipsilateral projections). **(C')** Represents the piriform cortex at its frontal subdivision. The typical three-layer histology is indicated. Note that somatostatin cells are in layer II and mainly in layer III. Afterward, olfactory tract reaches the temporal lobe **(D)**, including the temporal subdivision of the piriform cortex, the cortical amygdala **(D')** and the most rostral portion of the entorhinal cortex **(D")**. Note that no specific layer topography exists within the amygdala. On the contrary well defined six layers can be observed in the entorhinal cortex. Scale bars for **A,B** = 1000 μm; **C,D** = 2000 μm; and **A'--D"** = 200 μm.](fnins-14-00096-g001){#F1}

Beside its cognitive and neuroendocrine functions ([@B57]), central SST is involved in olfactory information processing such as olfactory detection and discrimination behaviors ([@B26]; [@B33]). Alternatively, SST contributes to additional actions related to olfaction, namely anxiety or fear-related behaviors ([@B61]). During the first relay of olfactory information SST regulates odor discrimination through SSTR2 receptor expressed by mitral cells ([@B26]; [@B33]). Furthermore, SST function related to the anterior olfactory nucleus, which constitutes the first relay from mitral cells, remains unknown. Piriform cortex is the main olfactory cortical area involved in the formation of odor percepts ([@B20]) and it regulates both excitation and inhibition network by inhibiting other interneurons, including other somatostatin cells and principal cells and they may help to discriminate odor responses from background cortical activity ([@B24]). Moreover, SST cells regulate neurons by subtractive inhibition, which enhances the threshold for sensory input to trigger a response, that is independent of odor identity and intensity ([@B51]). Entorhinal cortex is involved in olfactory associative learning and recognition abilities ([@B32]). However, SST participation on olfactory processing within these areas is still poorly unknown. Nevertheless, SST distribution differs between mouse and rat ([@B8]).

Somatostatin and Parkinson's Disease {#S2}
====================================

Olfactory deficits have been reported as a preclinical risk factor for the development of PD ([@B35]). Moreover, the main pathological marker (accumulation of intracellular aggregates of α-synuclein forming Lewy bodies) is present in key olfactory structures, such as the anterior olfactory nucleus, from the earliest stages of disease progression ([@B12]).

Postmortem studies have reported that around 8% of cells containing Lewy pathology in the olfactory bulb are somatostatinergic cells, as compared to more than 50% of calcium-binding protein-expressing cells, particularly those expressing calbindin (CB) and calretinin (CR) and to a lesser extent parvalbumin-expressing cells (PV) ([@B54]). Studies comparing control vs. PD cases have revealed a significant decrease of SST and an increase of PV in the AON ([@B53]). These low percentages of co-localization of SST with Lewy pathology were also observed in the amygdala ([@B18]). Studies carried out in control, non-demented and demented PD cases also suffering from Alzheimer's disease demonstrated that only comorbid cases showed a 40% reduction of SST in the frontal and temporal cortices ([@B3]).

Somatostatin and Alzheimer's Disease {#S3}
====================================

The two main hallmarks of AD are extracellular deposition of amyloid-β (Aβ~1--42~) forming senile plaques and intracellular aggregates of tau protein forming neurofibrillary tangles ([@B48]). Both have been described as affecting the olfactory system, while tau is involved early, especially in the entorhinal cortex ([@B4]) and within the anterior olfactory nucleus ([@B2]). These features make the olfactory system especially vulnerable to early stage disease progression.

Reduction of SST in AD was reported 40 years ago ([@B11]). Nowadays, SST reduction in the early stages and its involvement in memory formation is well established ([@B15]). Other interneuron subpopulations such as CR or CB cells are reduced as well. Interestingly, as in PD, PV cells are not reduced in olfactory cortex ([@B44]). However, most studies have focused on the hippocampal formation, and olfactory system studies are scarce. Moreover, olfactory deficits, namely hyposmia and anosmia, appear in patients with mild cognitive impairment (MCI) and correlate with later evolution to AD dementia ([@B13]). Despite SST reduction being common within most olfactory areas ([@B45], [@B44]) olfactory explicit memory (namely odor identification and odor recognition, which are hippocampus dependent) is thought to be more deeply involved in AD as compared with olfactory threshold detection or implicit memory tasks such as habituation or sensitization ([@B37]). Nonetheless, the use of standardized tests remains controversial.

Somatostatin dysfunction is involved early in memory deficits observed in mouse models and may be affected by Aβ~1--42~ deposition ([@B47]). Remarkably, SST is the main binder of Aβ~1--42~ and can encourage the formation of different Aβ~1--42~ oligomers by acquiring amyloid properties ([@B58]; [@B50]). In agreement with this, SST and Aβ~1--42~ levels in the cerebrospinal fluid seem to be correlated ([@B14]) and co-localization of both in the human brain, including the olfactory cortex, are widespread histological features ([@B45], [@B44]). In fact, SST has been highlighted as a regulator of Aβ~1--42~ deposition ([@B43]). On the other hand, positron emission tomography results link olfactory impairment with tau rather than amyloid deposition ([@B41]). However, we cannot rule out the aging influence on olfactory impairment and not only tau accumulation itself ([@B29]). Interestingly, cortistatin (a neuropeptide related to SST) can induce the phosphorylation of tau and may be linked with AD pathophysiology ([@B42]).

Overview {#S4}
========

The olfactory system is early and severely affected by pathologic proteins in both AD and PD. On the other hand, SST is unequally involved, being strongly involved in AD and having a weaker effect in PD. SST is reduced during the early stages of AD, including the olfactory areas, and may be related to Aβ~1--42~ and/or tau pathophysiology. However, the knowledge of both SST and SSTRs involvement in the human olfactory system is very scarce. Olfactory deficits may be related to SST deficiencies and to memory impairment due to tau deposition. In fact, SST is preserved in non-demented PD cases. Finally, anterior olfactory nucleus highlights as a key olfactory area; it is one of the earliest affected by tau accumulation and contains high quantities of SST. Further studies may indicate which olfactory deficiencies are more accurate for early diagnoses and help to refine the scope of SST as a potential therapeutic target.
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